At 4.5% CAGR, Europe Peripheral Embolization Coils Market is Projected to be Worth US$ 268.44 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe peripheral embolization coils market was valued at US$ 189.47 million in 2023 and is expected to reach US$ 268.44 million by 2031, registering a CAGR of 4.5% from 2023 to 2031. Expanding range of applications of embolization coils and increase in incidence of cancer are among the critical factors attributed to drive the Europe peripheral embolization coils market growth.

Companies operating in the peripheral embolization coils market constantly focus on new product launches and marketing approval, which helps them improve their sales. A few of the noteworthy developments in the peripheral embolization coils market are mentioned below. In January 2024, the National Medical Products Administration provided marketing approval for the ZYLOX Phoenix Peripheral Detachable Fibered Coil Embolization System manufactured by Zylox-Tonbridge Medical Technology Co Ltd. Peripheral vascular intervention is the most prevalent application of this embolization coil system. Embolization treatment of visceral aneurysms, endoleak management of abdominal aortic aneurysms, hemoptysis, and arteriovenous fistula are the other important clinical applications of the system, which are internationally recognized for their safety and efficacy. In April 2022, Boston Scientific Corporation received 510(k) clearance from the US Food and Drug Administration (FDA) for the EMBOLD Fibered Detachable Coil designed to block or reduce the blood flow rate in the peripheral vasculature. The newest addition to Boston Scientific's interventional oncology portfolio was designed for use in various embolization procedures, necessarily minimally invasive treatments intended to block one or more blood vessels to obstruct or reduce blood flow. The EMBOLD Fibered Detachable Coil features a single platform consisting of three coils, making it simpler for physicians to address various patient needs and anatomies. Thus, new product developments and marketing approvals are anticipated to create opportunities for growth of the peripheral embolization coils market during the forecast period.

On the contrary, the complications arising during or after embolization hampers the growth of Europe peripheral embolization coils market.

Based on type, the Europe peripheral embolization coils market is bifurcated into detachable coil and pushable coil. The detachable coil segment held 70.2% market share in 2023, amassing US$ 133.00 million. It is projected to garner US$ 189.98 million by 2031 to register 4.6% CAGR during 2023-2031.

In terms of material, the Europe peripheral embolization coils market is categorized into platinum, platinum & hydrogel, and platinum tungsten alloy. The platinum segment held 49.5% share of Europe peripheral embolization coils market in 2023, amassing US$ 93.72 million. It is projected to garner US$ 137.00 million by 2031 to register 4.9% CAGR during 2023-2031

By application, the Europe peripheral embolization coils market is segmented into bleedings & trauma, malformations, tumours, visceral aneurysm, endoleak type II, and varicose veins. The bleedings & trauma segment held 38.1% share of Europe peripheral embolization coils market in 2023, amassing US$ 72.13 million. It is projected to garner US$ 106.23 million by 2031 to expand at 5.0% CAGR from 2023 to 2031.

Based on country, the Europe peripheral embolization coils market is categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.5% share of Europe peripheral embolization coils market in 2023. It was assessed at US$ 50.21 million in 2023 and is likely to hit US$ 72.10 million by 2031, registering a CAGR of 4.6% during 2023-2031.

Key players operating in the Europe peripheral embolization coils market are Medtronic Plc; Penumbra, Inc.; Balt; Boston Scientific Corp; Cook Medical Holdings LLC; Wallaby Medical; Spartan Micro Inc.; and Terumo Corp., among others.

• In June 2022, Balt has opened a second office in France. The Paris office will house members of the sales, marketing, clinical affairs, finance, IT, legal, HR and communication teams.
• In April 2022, Wallaby Medical announced the acquisition pf phenox GmbH, including phenox's femtos GmbH ("femtos"), (together "phenox"), a German-based global innovation and technology leader in the neurovascular space. The acquisition is one of the largest cross-border transactions in the medical device industry globally in recent years and is driven by strong growth opportunities in both product portfolio and geographic coverage. It will enable the combined company to become a global leader in providing a wide range of neurovascular technologies and solutions to its customers and patients around the world, including in the U.S., China, Europe, Japan and other international markets.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com